BD chooses Spain as home for new high-tech manufacturing facility
Zaragoza plant will produce devices such as prefillable syringes to deliver vaccines and other biologics
After announcing at the end of 2020 its intention to build a new plant in Europe, BD (Becton, Dickinson and Company) has chosen Zaragoza located in the Aragon region of Spain.
The company has said it plans to begin constructing the €165 million ($200 million USD) high-tech manufacturing plant in late 2021. It will produce devices such as prefillable syringes to deliver vaccines and other biologics and will become BD's fourth manufacturing plant in Spain.
The site will have an initial workforce of 150 people and encompass an area of 8,000 m2 (86,000 sq. ft). By 2030 it is expected to employ up to 600 people with an area of 30,000 m2 (323,000 sq. feet).
The company said its new facility will meet high sustainability and eco-efficiency standards, and it will be a fully digital site, incorporating the latest in intelligent and autonomous technologies, also knowns as Industry 4.0 solutions.
Eric Borin, worldwide president of BD Pharmaceutical Systems, said the plant will focus on producing "drug delivery devices primarily for pharmaceutical companies that supply the European market with drugs in prefillable syringes such as vaccines and other biologic drugs".
He added that the plant will also provide additional capacity for vaccination campaigns similar to the current one being rolled out in response to the COVID-19 pandemic.
Last December, BD announced its plan to invest $1.2 billion USD over 4 years to expand and upgrade its manufacturing capacity and technology for prefillable syringes and advanced drug delivery systems. Part of this investment will fund the new Zaragoza site.
The company's other three Spanish sites - located in San Agustín de Guadalix, Fraga and Almaraz - produce a total 10 billion devices each year. The Fraga site is a major producer of COVID-19 vaccination devices and is expected to be synergistic with the new site.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance